

Literatura

1. Hanauer SB. Maintenance infliximab for Crohn's disease. The ACCENT I randomized trial. *Lancet* 2002;359,4:1541-1549.
2. Sands B. Infliximab maintenance therapy for fistulating Crohn's disease (ACCENT II). *New England Journal Medical* 2004;350,9:876-885.
3. Rutgeerts P, Feagen BG, Olson A, et al. A randomised placebo controlled trial of infliximab for active ulcerative colitis: the ACT-1 trial. DDW, Chicago 2005, ID 689.
4. Sandborn WJ, Rachmilewitz D, Hanauer SB, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the ACT-2 trial. DDW, Chicago 2005, ID 688.
5. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab of inflammatory bowel disease: a single cohorte study. *Gut* 2008;57 (Suppl):A260.
6. Peyrin-Biroulet, Delterne P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonist in Crohn's disease: meta-analysis of placebo-controlled trials. *Clin Gastroent Hepatol* 2008;6:664-653.
7. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab: results from single-centre cohort in 614 patients with Crohn's disease. *Gut* 2009;58:492-500.
8. D'Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? *Am J Gastroenterol* 2001;106:199-212.
9. Lukáš M, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. *Čes Slov Gastroent Hepatol* 2008;62(5):285-291.
10. Zbořil V. Biologická terapie v gastroenterologii. *Čes Slov Gastroent Hepatol* 2007;61(6):287-292.
11. Rutgeerts P. Comparison of Schedule and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology* 2004;126:402-413.

12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 2006;130:323–333.
13. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut* published online 13 Feb 2007, doi: 10.1136/gut.2006.106781.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007;132:52–65.
15. Sandborn WJ. Gauging adalimumab efficacy in infliximab non-responders GAIN trial. ACG meeting, Las Vegas 2006.
16. Han PD, Cohen RD. Management immunogenic response to infliximab – treatment implication for patients with Crohn's disease. *Drugs* 2004;64(16):1767–1777.
17. Vermiere S, Norman M, Van Assche G. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut* 2007;56(9):1226–1231.
18. Van Assche G, Paintaud G, Magdelaine C, et al. Concomitant immunosuppression does not impact on the outcome of maintenance infliximab therapy. Final results of IMID trial. DDW, Washington 2007, DC.
19. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with Schedule infliximab maintenance: A randomized trial. *Gastroenterology* 2008;134:1861–1868.
20. Colombel JP, et al. A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. SONIC study. *J Crohn's Colitis* 2009;3:S45–46.
21. Toruner M, Loftus Jr. EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008;134(4):929–936.
22. European Association for the Study of Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. *B J Hepatol* 2009;50(2):227–242.
23. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF alpha therapy in rheumatoid arthritis et spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology (Oxford)* 2006;45(10):1294–1297.
24. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab tumor necrosis alpha neutralizing agent. *N Engl J Med* 2001;345(15):1098–1104.

25. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *New Engl J Med* 2010; 362:1383-1395.
26. Ramos Casals M, Pilar-Brito Z, Cuadrado M-J, et al. Vasculitis induced by tumor necrosis factor-targeted therapies. *Current Rheumatology Reports* 2008;10:442-448, *Autoimmunity Reviews* 2010;9:188-193.
27. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. *J Pediatr Gastroenterol Nutr* 2009;48:386-388.
28. Casparsen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow up evaluation of malignancy and mortality. *Clin Gastroenterol Hepatol* 2008;6(11):1212-1217.